About 1-acyl-sn-glycerol-3-phosphate acyltransferase beta
1-acyl-sn-glycerol-3-phosphate acyltransferase beta (AGPAT2) is a protein
from Homo sapiens identified by UniProt accession
O15120, 278 residues long.
MolForge cross-references it against 0 known binders and
179 disease associations.
Target properties
| Protein name | 1-acyl-sn-glycerol-3-phosphate acyltransferase beta |
|---|
| UniProt accession | O15120 |
|---|
| Gene | AGPAT2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 278 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (179)
Diseases linked to this target (Open Targets).
- Berardinelli-Seip congenital lipodystrophy · score 0.57
- congenital generalized lipodystrophy · score 0.55
- Lipodystrophy · score 0.37
- lipodystrophy · score 0.37
- phosphatidylcholine measurement · score 0.25
- genetic disorder · score 0.19
- glioblastoma multiforme · score 0.18
- monogenic diabetes · score 0.18
- breast adenocarcinoma · score 0.18
- prostate carcinoma · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O15120-F1 | alphafold | PREDICTED | 91.10 | — |
Amino-acid sequence (278 residues)
MELWPCLAAA LLLLLLLVQL SRAAEFYAKV ALYCALCFTV SAVASLVCLL RHGGRTVENM SIIGWFVRSF KYFYGLRFEV RDPRRLQEAR PCVIVSNHQS ILDMMGLMEV LPERCVQIAK RELLFLGPVG LIMYLGGVFF INRQRSSTAM TVMADLGERM VRENLKVWIY PEGTRNDNGD LLPFKKGAFY LAVQAQVPIV PVVYSSFSSF YNTKKKFFTS GTVTVQVLEA IPTSGLTAAD VPALVDTCHR AMRTTFLHIS KTPQENGATA GSGVQPAQ
Explore 1-acyl-sn-glycerol-3-phosphate acyltransferase beta with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets